OncologyEducation· @OncEd · X·· 3 天前评分70
正文 · 原文
HERIZON-GEA-01 at #ESMO26: zanidatamab + chemo improved OS vs. trastuzumab + chemo in HER2+ gastroesophageal cancer (HR 0.76); the tislelizumab triplet kept its OS benefit (HR 0.65). Kohei Shitara, MD (@KoheiShitara), explains.
Watch now: https://bit.ly/4i86pYg
17 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA79按 Rapid oral 1: Gastrointestinal tumour, upper digestive 对上
Zanidatamab (zani) + chemotherapy (CT) ± tislelizumab (TIS) for first-line (1L) HER2-positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (mGEA): Second interim analysis (IA) from HERIZON-GEA-01
https://esmocongress.esmo.org来源：OncologyEducation · x.com